Brawn Nutrition Tesofensine 50mcg 60 caps

Description

Brawn Nutrition Tesofensine 50mcg 60 Caps

Brawn Nutrition Tesofensine 50mcg 60 Caps is a single-compound capsule product containing a declared 50mcg of tesofensine per capsule.

Each container provides 60 capsules. The product is supplied in a compact bottle displaying the Brawn Nutrition branding, the Tesofensine product name and the declared capsule count. Available retailer information consistently reports a specification of 50mcg per capsule.

What is tesofensine?

Tesofensine, also known by the research designation NS2330, is an investigational synthetic small molecule that inhibits the reuptake of serotonin, noradrenaline and dopamine. It is therefore described as a triple monoamine reuptake inhibitor.

Tesofensine is not a peptide, SARM, vitamin, mineral or conventional herbal ingredient. It has been investigated as a pharmaceutical compound, including in clinical research relating to obesity and appetite regulation.

Commercial descriptions frequently associate tesofensine with appetite suppression, increased energy expenditure and weight reduction. These effects should not be presented as guaranteed benefits of this particular commercial product, because clinical research on a pharmaceutical substance does not confirm the quality, identity, safety or effectiveness of an independently marketed capsule product.

Product specifications

• Brand: Brawn Nutrition
• Product name: Tesofensine
• Declared compound: Tesofensine
• Research designation: NS2330
• Declared amount: 50mcg per capsule
• Package size: 60 capsules
• Product form: capsules
• Compound category: investigational triple monoamine reuptake inhibitor

The complete composition, capsule shell, excipients, batch number, expiry date, storage conditions and warnings should be verified against the physical packaging before publication or dispatch.

Product presentation and verification

A complete catalogue listing should allow customers to verify:

• the Brawn Nutrition branding,
• the Tesofensine product name,
• the declared 50mcg specification,
• the 60-capsule package size,
• the complete quantitative ingredient panel,
• the batch and expiry information,
• the details of the manufacturer or responsible operator,
• the condition of the original safety seal.

The physical label should remain the primary source for the final specifications. The product should not be distributed when its seal is damaged, the label appears altered or the physical composition differs from the online listing.

Safety and regulatory information

Tesofensine affects central monoamine neurotransmission. Clinical research has reported adverse effects including dry mouth, headache, nausea, insomnia, diarrhoea and constipation. Studies and development protocols have also described increases in heart rate and, at some doses, blood pressure, which led researchers to examine combinations with a beta blocker to mitigate cardiovascular effects.

Tesofensine remains subject to pharmaceutical development and regulatory review. The developer reports that an application concerning its use as an obesity medicine is under review in Mexico; this does not constitute authorisation for a Brawn Nutrition capsule product in Poland or the European Union.

The presence of the wording “food supplement” on a commercial label does not by itself determine the product’s legal classification.

Information for tested athletes

Tesofensine is specifically listed in section S6 of the 2026 WADA Prohibited List as a stimulant prohibited in competition. Athletes should remember that a substance taken before the competition period may still produce a positive result if it remains detectable during competition.

This description is provided solely for accurate product identification and catalogue-reference purposes. It does not provide medical advice, dosing instructions, weight-loss guidance or guarantees of results.